FDA Launches Regulatory Accelerator to Boost Medical Device Software Innovation

On 24 July 2025, the U.S. Food and Drug Administration (FDA) introduced its Regulatory Accelerator initiative to support developers of digital health devices. This new initiative provides targeted tools and guidance to help innovators navigate compliance requirements more efficiently for medical device software, ultimately aiming to accelerate time-to-market for safe and effective digital health technologies. 

What’s Included in the Initiative: 

The Regulatory Accelerator introduces several resources to support compliance across the software development lifecycle: 

• A Resource Index for Digital Health Device Innovators, which acts as a visual guide to FDA tools, relevant guidance documents, and opportunities for engagement with the FDA. 

• Early Orientation Meetings are emphasized as a best practice for sponsors looking to engage with the FDA early in the development process, especially for marketing submissions involving software-based medical devices. 

• A Medical Device Software Guidance Navigator, a tool designed to help innovators quickly locate applicable FDA guidances. It also aligns with the electronic Submission Template And Resource (eSTAR) system, offering smoother compliance throughout product development. 

The initiative is designed specifically to help first-time and emerging innovators understand FDA processes related to the regulatory review and oversight of medical device software. 

Why It Matters:

The Regulatory Accelerator improves regulatory clarity and aligns with FDA’s ongoing digital transformation goals. It aims to enhance submission quality, reduce review time, and increase collaboration between innovators and the FDA. This initiative will support safer, faster deployment of digital health solutions without adding compliance burden. 

Who Should Take Note:

This update is particularly relevant for Regulatory Affairs teams, digital health product developers, compliance officers, and medical device software teams. It is also essential for those preparing marketing submissions involving software components in medical devices.

Next Steps: 

Stakeholders are advised to: 

• Explore the Resource Index and Guidance Navigator to identify applicable FDA tools and documents. 

• Familiarize themselves with eSTAR alignment for smoother submissions. 

• Schedule Early Orientation Meetings with the FDA when preparing for software-based device marketing submissions. 

Proactively engaging with these resources will support successful compliance strategies and reduce delays in regulatory review.

As regulatory landscapes continue to evolve with advancing technologies, it is critical for innovators to stay aligned with FDA processes.  
RegASK is an AI-driven platform that helps life sciences and MEDtech companies navigate complex regulatory environments with timely monitoring, regulatory intelligence, and automated submission support.

Learn more about RegASK!